Ignet
v2.0 Sign In

Gene Information

Gene symbol: NUDT6

Gene name: nudix (nucleoside diphosphate linked moiety X)-type motif 6

HGNC ID: 8053

Synonyms: gfg-1, gfg, FGF2AS, FGF-AS

Related Genes

# Gene Symbol Number of hits
1 DES 1 hits
2 FGF1 1 hits
3 FGF2 1 hits

Related Sentences

# PMID Sentence
1 8200474 Analysis of the fibroblast growth factor-2 (FGF-2 or bFGF) proteins during chicken embryonic pattern formation and organogenesis revealed that three isoforms (18.5, 20.0, and 21.5 kDa) were synthesized by alternative translation initiation from one coding region.
2 8766154 We have used avidin-biotin-enhanced indirect immunohistochemistry to localize FGF-1 and FGF-2 in the rat kidney.
3 8766154 We have used avidin-biotin-enhanced indirect immunohistochemistry to localize FGF-1 and FGF-2 in the rat kidney.
4 8766154 Intracellular immunoreactivity for FGF-1 and FGF-2 is co-localized in visceral (podocytes) and parietal (Bowman's capsule) glomerular epithelial cells, S3 segments of proximal tubules, distal tubules and collecting ducts in the cortex, and thick ascending limbs and collecting ducts in the medulla.
5 8766154 Intracellular immunoreactivity for FGF-1 and FGF-2 is co-localized in visceral (podocytes) and parietal (Bowman's capsule) glomerular epithelial cells, S3 segments of proximal tubules, distal tubules and collecting ducts in the cortex, and thick ascending limbs and collecting ducts in the medulla.
6 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
7 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
8 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
9 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
10 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
11 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
12 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
13 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
14 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
15 8995747 Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.
16 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
17 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
18 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
19 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
20 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
21 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
22 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
23 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
24 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
25 8995747 In the present study, two series of experiments were done with PAN nephropathy rats given fibroblast growth factor 2 (FGF2) or FGF2 neutralizing antibodies.
26 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
27 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
28 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
29 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
30 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
31 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
32 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
33 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
34 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
35 8995747 In the first series of experiments, a dose of 10 micrograms of FGF2 (FGF2 group), 40 micrograms of an FGF2 neutralizing antibody (Anti-FGF2 group) or an equal volume of physiological saline (Control group) was administered for four days after PAN injection.
36 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
37 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
38 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
39 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
40 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
41 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
42 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
43 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
44 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
45 8995747 Urinary protein increased more in the FGF2 group than in the other two groups.
46 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
47 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
48 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
49 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
50 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
51 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
52 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
53 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
54 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
55 8995747 PCNA (+) glomerular cells were found in decreasing order in groups FGF2, Control and Anti-FGF2.
56 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
57 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
58 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
59 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
60 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
61 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
62 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
63 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
64 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
65 8995747 Staining for desmin, a marker of podocyte injury, was significantly reduced in the Anti-FGF2 group.
66 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
67 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
68 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
69 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
70 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
71 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
72 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
73 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
74 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
75 8995747 Glomerular adhesive lesions were found in decreasing order in groups FGF2, Control and Anti-FGF2.
76 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
77 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
78 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
79 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
80 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
81 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
82 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
83 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
84 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
85 8995747 The second series of experiments was designed to study the effects of FGF2 neutralizing antibody (40 micrograms for 5 days after PAN injection, in MoAb group) on severely damaged podocytes caused by repeated (two courses) injections in the PAN nephropathy rats.
86 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
87 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
88 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
89 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
90 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
91 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
92 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
93 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
94 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
95 8995747 It was supposed that FGF2 would promote the formation of adhesive lesions by stimulating the proliferation of podocytes and epithelial cells of Bowman's capsule.
96 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
97 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
98 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
99 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
100 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
101 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
102 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
103 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
104 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.
105 8995747 Additionally, FGF2 itself was thought to impair podocytes because of the increasing desmin score and proteinuria.